Alx Oncology Holdings (ALXO) Common Equity (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Common Equity data on file, last reported at $151.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 71.41% year-over-year to $151.3 million; the trailing twelve-month figure through Mar 2026 stood at $151.3 million (up 71.41% YoY), and the FY2025 full-year result was $26.0 million, down 77.13% from the prior year.
• Common Equity advanced to $151.3 million in Q1 2026, from $26.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $343.6 million in Q1 2022 to a low of $26.0 million in Q4 2025.
• A 5-year average of $174.7 million and a median of $164.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 77.13% in 2025 and jumped 71.41% in 2026, its largest moves.
• Tracing ALXO's Common Equity over 5 years: stood at $263.5 million in 2022, then fell by 27.99% to $189.7 million in 2023, then tumbled by 40.11% to $113.6 million in 2024, then slumped by 77.13% to $26.0 million in 2025, then jumped by 482.53% to $151.3 million in 2026.
• Business Quant data shows ALXO's Common Equity at $151.3 million in Q1 2026, $26.0 million in Q4 2025, and $44.8 million in Q3 2025.